Data on Advaxis’ Clinical Programs to be Presented at Upcoming Medical Meetings

On January 30, 2020 Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, reported the following upcoming presentations at medical meetings (Press release, Advaxis, JAN 30, 2020, View Source [SID1234553711]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ASCO – Genitourinary Cancers Symposium February 12-15, 2020, San Francisco, California
Title: "KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab
on survival in metastatic, castration-resistant prostate cancer patients with or without
prior exposure to docetaxel"
Presenter: Dr. Mark N. Stein, Associate Professor, Division of Hematology/Oncology, Columbia University Medical Center
Abstract: 126, Poster number F6
Date: Thursday, February 13, 2020
Time: 11:30AM – 1:00 PM, 5:30PM – 6:30 PM PT

IASLC 2020 Targeted Therapies of Lung Cancer Meeting February 19-22, 2020, Santa Monica, California
Session: Immunotherapy Combinations
Title: A Phase 1 Study of ADXS-503 Alone and in Combination with Pembrolizumab in
Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Presenter: Dr. Jennifer Carlisle, Assistant Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University
Date: Saturday, February 22, 2020
Time: 7:00 am PT

Immuno-oncology 360° February 26-28, 2020, New York, New York
Session: IO Novel Technologies
Title: "Clinical Updates for Advaxis’ Pipeline of Lm-based Immunotherapies in
Oncology"
Presenter: Andres A. Gutierrez MD PhD – Advaxis’ Chief Medical Officer and Executive Vice President
Date: Thursday, February 27, 2020
Time: 11:00 am ET